

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicants: Philippa RADCLIFFE et al.

Title: TRANSGENIC ORGANISM

Appl. No.: Unassigned

Filing Date: 02/26/2002

Examiner: Unassigned

Art Unit: Unassigned

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, Applicants respectfully request that the above-identified application be amended as follows:

**In the Claims:**

In accordance with 37 C.F.R. §1.21, please substitute for claims 3, 8, 11, 12, 17 – 21, 23 and 24 the following rewritten version of the same claims. The changes are shown explicitly in the attached "Marked-up Version of Amended Claims."

3. (Once Amended) A method according to claim 1, wherein the expression vector is introduced in vivo or ex vivo.

8. (Once Amended) A method according to claim 1, wherein the cell is capable of giving rise to a germ line change.

11. (Once Amended) A method according to claim 8, wherein the cell is an oocyte, an oviduct cell, an ovarian cell, an ovum, an oogonium, a zygote, an ES cell, a blastocyte, a spermatocyte, a spermatid, a spermatozoa, or a spermatogonia.

12. (Once Amended) A method according to claim 1, wherein the cell is from an animal, or a yeast.

17. (Once Amended) A method according to claim 1, wherein the lentiviral expression vector is pseudotyped.

18. (Once Amended) A method according to claim 1, wherein the lentiviral expression vector does not contain any functional accessory genes.

19. (Once Amended) A method according to claim 1, wherein the NOI is operably linked to a constitutive, tissue-specific or an inducible promotor.

20. (Once Amended) A method according to claim 1, wherein the NOI encodes a therapeutic protein, is an antisense oligonucleotide, or encodes a ribozyme.

21. (Once Amended) A method according to claim 1, wherein the lentiviral expression vector is introduced into the cell via the umbilical cord, placenta, or amniotic fluid, uterus, gonads, or by intraperitoneal or intrahepatic administration.

23. (Once Amended) A transgenic cell produced by the method of claim 1.

24. (Once Amended) A transgenic organism which is generated from or obtainable by generation from a transgenic cell as defined in claim 1.

**REMARKS**

Applicants respectfully request that the foregoing amendments be made prior to examination of the present application. The amendments are made to correct multiple dependencies and do not change the scope of the invention.

Respectfully submitted,

Date February 26, 2002  
FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5427  
Facsimile: (202) 672-5399

By S. G. Reut, Reg. No. 28,768  
for Bernhard D. Saxe  
Attorney for Applicants  
Registration No. 28,665

10082122.022602

**MARKED UP VERSION OF AMENDED CLAIMS**

3. (Once Amended) A method according to claim 1, [or 2] wherein the expression vector is introduced in vivo or ex vivo.

8. (Once Amended) A method according to [any preceding claim] claim 1, wherein the cell is capable of giving rise to a germ line change.

11. (Once Amended) A method according to [any one of claims 8 to 10] claim 8, wherein the cell is an oocyte, an oviduct cell, an ovarian cell, an ovum, an oogonium, a zygote, an ES cell, a blastocyte, a spermatocyte, a spermatid, a spermatozoa, or a spermatogonia.

12. (Once Amended) A method according to [any preceding] claim 1, wherein the cell is from an animal, or a yeast.

17. (Once Amended) A method according to [any preceding] claim 1, wherein the lentiviral expression vector is pseudotyped.

18. (Once Amended) A method according to [any preceding] claim 1, wherein the lentiviral expression vector does not contain any functional accessory genes.

19. (Once Amended) A method according to [any preceding] claim 1, wherein the NOI is operably linked to a constitutive, tissue-specific or an inducible promotor.

20. (Once Amended) A method according to [any preceding] claim 1, wherein the NOI encodes a therapeutic protein, is an antisense oligonucleotide, or encodes a ribozyme.

21. (Once Amended) A method according to [any preceding] claim 1, wherein the lentiviral expression vector is introduced into the cell via the umbilical cord,

placenta, or amniotic fluid, uterus, gonads, or by intraperitoneal or intrahepatic administration.

23. (Once Amended) A transgenic cell produced by the method of [any preceding] claim 1.

24 (Once Amended) A transgenic organism which is generated from or obtainable by generation from a transgenic cell as defined in [any preceding] claim 1.